# EDGAR Filing Document

**Accession Number:** 0001803737
**File Stem:** 0001803737-26-000015
**Filing Date:** 2026-3
**Character Count:** 100757
**Document Hash:** 9578f069e5763429151e0187af6b76a1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001803737-26-000015.hdr.sgml**: 20260305

**ACCESSION NUMBER**: 0001803737-26-000015

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 50

**CONFORMED PERIOD OF REPORT**: 20260304

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260305

**DATE AS OF CHANGE**: 20260304

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Enhabit, Inc.
- **CENTRAL INDEX KEY:** 0001803737
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-HOME HEALTH CARE SERVICES [8082]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 472409192
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41406
- **FILM NUMBER:** 26723454

**BUSINESS ADDRESS:**
- **STREET 1:** 6688 N. CENTRAL EXPRESSWAY, SUITE 1300
- **CITY:** DALLAS
- **STATE:** TX
- **ZIP:** 75206
- **BUSINESS PHONE:** 4696216419

**MAIL ADDRESS:**
- **STREET 1:** 6688 N. CENTRAL EXPRESSWAY, SUITE 1300
- **CITY:** DALLAS
- **STATE:** TX
- **ZIP:** 75206

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Encompass Health Home Health Holdings, Inc.
- **DATE OF NAME CHANGE:** 20200218

?xml version='1.0' encoding='ASCII'? ehab-20260304

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K** 

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (date of earliest event reported): March 4, 2026

**Enhabit, Inc.** 

(Exact name of Registrant as specified in its Charter)

---

| | | |
|:---|:---|:---|
| **<u>Delaware</u>** | **<u>001-41406</u>** | **<u>47-2409192</u>** |
| (State or Other Jurisdiction | (Commission File Number) | (IRS Employer |
| of Incorporation) | | Identification No.) |

---

**<u>6688 N. Central Expressway, Suite 1300, Dallas, Texas 75206</u>**

(Address of Principal Executive Offices, Including Zip Code)

**<u>(214) 239-6500</u>**

(Registrant's Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

---

| | |
|:---|:---|
| ☐ | Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☑ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |

---

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, par value $0.01 per share | EHAB | New York Stock Exchange |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. &nbsp;&nbsp;&nbsp;&nbsp;Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 2.02.** *Results of Operations and Financial Condition.\** 

On March 4, 2026, Enhabit, Inc. (the "Company") issued a press release reporting the financial results of the Company for the quarter and year ended December 31, 2025. A copy of the press release is attached to this report as Exhibit 99.1 and incorporated herein by reference.

**Item 7.01.** *Regulation FD Disclosure.\**

A copy of the supplemental information is attached to this report as Exhibit 99.2 and incorporated herein by reference.

**Item 9.01.** *Financial Statements and Exhibits.*

(d)&nbsp;&nbsp;&nbsp;&nbsp;Exhibits.

---

| | |
|:---|:---|
| **<u>Exhibit Number</u>** | **<u>Description</u>** |
| <u>[99.1](q42025enhabitearningsrelea.htm)</u> | <u>[Press release of Enhabit, Inc., dated March](q42025enhabitearningsrelea.htm)[4](q42025enhabitearningsrelea.htm)[, 202](q42025enhabitearningsrelea.htm)[6](q42025enhabitearningsrelea.htm)[.](q42025enhabitearningsrelea.htm)</u>\* |
| <u>[99.2](enhabit_earningsxslidesx.htm)</u> | <u>[Supplemental Information of Enhabit, Inc.\*](enhabit_earningsxslidesx.htm)</u> |
| 104 | Cover Page Interactive Data File - the cover page iXBRL tags are embedded within the Inline XBRL document. |

---

\* The information in Item 2.02 and Item 7.01, including Exhibit 99.1 and Exhibit 99.2, is being "furnished" and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section and shall not be incorporated into any filing under the Securities Act of 1933, as amended, or the Exchange Act, unless specifically identified as being incorporated therein by reference.

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| ENHABIT, INC. | ENHABIT, INC. | ENHABIT, INC. |
| By: | /s/ Dylan Black | /s/ Dylan Black |
|  | Name: | Dylan Black |
|  | Title: | General Counsel |

---

Dated: March 4, 2026

## Exhibit 99.1

**Exhibit 99.1**

![enhabit_hhhxlogoxverticalx.jpg](enhabit_hhhxlogoxverticalx.jpg)

**Enhabit Reports Fourth Quarter 2025 Financial Results**

DALLAS, TX – March 4, 2026 – Enhabit, Inc. (NYSE: EHAB), a leading home health and hospice care provider, today reported its results of operations for the fourth quarter ended Dec. 31, 2025.

"Our fourth quarter 2025 results capped a pivotal year for Enhabit, delivering an emerging growth story with year over year increases in patient census, revenue and Adjusted EBITDA," said Barb Jacobsmeyer, CEO and president of Enhabit. "The consistent execution of our strategy throughout the year materially improved free cash flow, enabling us to further strengthen our balance sheet, positioning us well to accelerate growth and investment in 2026."

**QUARTERLY PERFORMANCE - CONSOLIDATED**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net service revenue of $270.4 million

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net loss attributable to Enhabit, Inc. of $38.7 million

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted EBITDA of $28.0 million

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Diluted loss per share of $0.76

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted diluted earnings per share of $0.14

**RECENT COMPANY HIGHLIGHTS**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Announced entry into a definitive agreement (the "Merger Agreement") to be acquired by Kinderhook Industries, LLC ("Kinderhook") for $13.80 per share.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• On Feb. 26, 2026, the company entered into an amended and restated credit agreement with a maturity date of February 2031 that consists of a $315.0 million senior secured term loan A facility and a $160.0 million senior secured revolving credit facility.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Home health year-over-year admissions growth of 7.3% with non-Medicare admissions growth of 16.0%; 8.1% total admission growth when normalized for branches closed in 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Home health average daily census (ADC) growth of 6.4% compared to prior year; continued stabilization of Medicare ADC decline, down 4.0% year over year and 1.7% sequentially.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Home health cost per patient day decreased 3.5% year over year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Hospice ADC grew 9.9% year over year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ ADC increased sequentially every quarter since Q1 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Hospice admissions increased 0.8% year over year; 3% when normalized for branches closed in 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Hospice net service revenue of $63.6 million; Adjusted EBITDA increased 2.3% year over year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Hospice cost per patient day increased 0.6% year over year.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Total net service revenue of $270.4 million; consolidated Adjusted EBITDA grew 11.6% year over year and 3.7% sequentially to $28.0 million.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Opened four de novo locations in Q4 2025; 10 total de novo locations in 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Consistent de-levering of balance sheet with the eighth straight quarter of debt prepayment, inclusive of an additional $20.0 million prepayment made in Q1 of 2026.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ $125.0 million reduction in total bank debt from Q4 2023 resulting in an annualized $22 million cash interest savings.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ Reduced bank debt by $15.0 million in the fourth quarter, yielding a leverage ratio of 3.7x.

**TRANSACTION WITH KINDERHOOK** 

As previously announced on Feb. 23, 2026, Enhabit has entered into the Merger Agreement to be acquired by Kinderhook, a middle-market private equity firm, for $13.80 per share in cash, or a total enterprise value of approximately $1.1 billion (the "Merger"). The Merger is expected to close in the second quarter of 2026, subject to stockholder approval and other customary closing conditions.

As previously disclosed, given the pending Merger, Enhabit will not be hosting an earnings conference call, and is suspending its practice of providing financial guidance.

------

**FINANCIAL RESULTS**

**Consolidated**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| ***($ in millions, except per share data)*** | **Q4** | **Q4** | **Q4** | **Q4** |  ***'25 vs. '24*** |
| ***($ in millions, except per share data)*** | **2025** | **2025** | **2024** | **2024** |  ***'25 vs. '24*** |
| Home health net service revenue | $206.8 | $206.8 | $200.4 | $200.4 | *3.2%* |
| Hospice net service revenue | 63.6 | 63.6 | 57.8 | 57.8 | *10.0%* |
| **&nbsp;&nbsp;&nbsp;&nbsp;Total net service revenue** | **$270.4** | **$270.4** | **$258.2** | **$258.2** | ***4.7%*** |
|  | *% of revenue* |  | *% of revenue* |  |  |
| Cost of service | *51.3%* | $138.7 | *51.5%* | $133.1 | *4.2%* |
| &nbsp;&nbsp;&nbsp;&nbsp;*Gross margin* | *48.7%* | 131.7 | *48.5%* | 125.1 | *5.3%* |
| General and administrative expenses | *38.2%* | 103.2 | *38.7%* | 99.8 | *3.4%* |
| &nbsp;&nbsp;&nbsp;&nbsp;*Total operating expenses* | *89.5%* | $241.9 | *90.2%* | $232.9 | *3.9%* |
| Other income | (0.1) | (0.1) |  |  |  |
| Net income attributable to noncontrolling interests  | $0.4 | $0.4 | $0.2 | $0.2 |  |
| **Adjusted EBITDA**<sup>(1)</sup> | **$28.0** | **$28.0** | **$25.1** | **$25.1** | ***11.6%*** |
| ***&nbsp;&nbsp;&nbsp;&nbsp;Adjusted EBITDA margin***<sup>(1)</sup> | ***10.4%*** | ***10.4%*** | ***9.7%*** | ***9.7%*** |  |
| **Impairment of goodwill** | **$44.7** | **$44.7** | **$53.8** | **$53.8** | ***(16.9)%*** |
| **Net income (loss) attributable to Enhabit, Inc.** | **$(38.7)** | **$(38.7)** | **$(46.0)** | **$(46.0)** | ***15.9%*** |
| **Reported diluted EPS** | **$(0.76)** | **$(0.76)** | **$(0.92)** | **$(0.92)** | ***(17.4)%*** |
| **Adjusted diluted EPS**<sup>(1)</sup> | **$0.14** | **$0.14** | **$0.04** | **$0.04** | ***250.0%*** |
| **General and administrative expenses in the above table exclude:** | **General and administrative expenses in the above table exclude:** | **General and administrative expenses in the above table exclude:** | **General and administrative expenses in the above table exclude:** | **General and administrative expenses in the above table exclude:** | **General and administrative expenses in the above table exclude:** |
| Loss (gain) on disposal of assets | $0.1 | $0.1 | $(0.2) | $(0.2) |  |
| Stock-based compensation expense | $6.8 | $6.8 | $3.9 | $3.9 |  |
| Unusual or nonrecurring items that are not typical of ongoing operations<sup>(2)</sup> | $1.1 | $1.1 | $1.1 | $1.1 |  |
| (1) See reconciliation of GAAP to Non-GAAP measures. | (1) See reconciliation of GAAP to Non-GAAP measures. | (1) See reconciliation of GAAP to Non-GAAP measures. | (1) See reconciliation of GAAP to Non-GAAP measures. | (1) See reconciliation of GAAP to Non-GAAP measures. | (1) See reconciliation of GAAP to Non-GAAP measures. |
| (2) Unusual or nonrecurring items in the three months ended December 31, 2025 include costs associated with restructuring activities and severance, nonroutine litigation and third-party legal and advisory fees related to shareholder, non-shareholder and other matters, and merger and acquisition activities; in the three months ended December 31, 2024, they include costs associated with nonroutine litigation and severance. | (2) Unusual or nonrecurring items in the three months ended December 31, 2025 include costs associated with restructuring activities and severance, nonroutine litigation and third-party legal and advisory fees related to shareholder, non-shareholder and other matters, and merger and acquisition activities; in the three months ended December 31, 2024, they include costs associated with nonroutine litigation and severance. | (2) Unusual or nonrecurring items in the three months ended December 31, 2025 include costs associated with restructuring activities and severance, nonroutine litigation and third-party legal and advisory fees related to shareholder, non-shareholder and other matters, and merger and acquisition activities; in the three months ended December 31, 2024, they include costs associated with nonroutine litigation and severance. | (2) Unusual or nonrecurring items in the three months ended December 31, 2025 include costs associated with restructuring activities and severance, nonroutine litigation and third-party legal and advisory fees related to shareholder, non-shareholder and other matters, and merger and acquisition activities; in the three months ended December 31, 2024, they include costs associated with nonroutine litigation and severance. | (2) Unusual or nonrecurring items in the three months ended December 31, 2025 include costs associated with restructuring activities and severance, nonroutine litigation and third-party legal and advisory fees related to shareholder, non-shareholder and other matters, and merger and acquisition activities; in the three months ended December 31, 2024, they include costs associated with nonroutine litigation and severance. | (2) Unusual or nonrecurring items in the three months ended December 31, 2025 include costs associated with restructuring activities and severance, nonroutine litigation and third-party legal and advisory fees related to shareholder, non-shareholder and other matters, and merger and acquisition activities; in the three months ended December 31, 2024, they include costs associated with nonroutine litigation and severance. |

---

------

**SEGMENT RESULTS**

**Home health**

---

| | | | |
|:---|:---|:---|:---|
| ***($ in millions)*** | **Q4** | **Q4** |  ***'25 vs. '24*** |
| ***($ in millions)*** | **2025** | **2024** |  ***'25 vs. '24*** |
| **Net service revenue:** |  |  |  |
| &nbsp;&nbsp;Medicare | $111.6 | $117.3 | (4.9)% |
| &nbsp;&nbsp;Non-Medicare | 93.4 | 80.8 | 15.6% |
| &nbsp;&nbsp;Private duty<sup>(1)</sup> | 1.8 | 2.3 | (21.7)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Home health net service revenue** | **206.8** | **200.4** | **3.2%** |
| Cost of service | 108.2 | 105.5 | 2.6% |
| &nbsp;&nbsp;*Gross margin* | *47.7* <br>*%* | *47.4* <br>*%* |  |
| General and administrative expenses | 61.3 | 59.1 | 3.7% |
| Net income attributable to noncontrolling interests  | 0.3 | 0.3 | — % |
| **Segment Adjusted EBITDA**<sup>(2)</sup> | **$37.0** | **$35.5** | **4.2%** |
| &nbsp;&nbsp;*Segment Adjusted EBITDA margin*<sup>(2)</sup> | *17.9* <br>*%* | *17.7* <br>*%* |  |
| **Operational metrics (actual amounts)** |  |  |  |
| **Medicare:** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Admissions | **22196** | 23121 | (4.0)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Recertifications | **15203** | 16300 | (6.7)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Completed episodes | **38077** | 39104 | (2.6)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Average daily census | **19030** | 19818 | (4.0)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Visits | **490281** | 560002 | (12.5)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Visits per episode | **12.9** | 14.3 | (9.8)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Revenue per episode | **$2931** | $3000 | (2.3)% |
| **Non-Medicare:** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Admissions | **34582** | 29810 | 16.0% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Recertifications | **14840** | 13541 | 9.6% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Average daily census | **23294** | 19968 | 16.7% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Visits | **574023** | 533618 | 7.6% |
| **Total:** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Admissions | **56778** | 52931 | 7.3% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Same-store total admissions growth* |  |  | *7.2* <br>*%* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Recertifications | **30043** | 29841 | 0.7% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Same-store total recertifications growth* |  |  | *0.7* <br>*%* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Average daily census | **42324** | 39786 | 6.4% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Visits | **1064304** | 1093620 | (2.7)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Visits per episode | **12.5** | 13.9 | (10.1)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cost per visit | **$102** | $95 | 7.1% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Revenue per patient day | **$53.1** | $54.7 | (2.9)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cost per patient day | **$27.8** | $28.8 | (3.5)% |
| (1) Private duty represents long-term comprehensive hourly nursing medical care. | (1) Private duty represents long-term comprehensive hourly nursing medical care. | (1) Private duty represents long-term comprehensive hourly nursing medical care. | (1) Private duty represents long-term comprehensive hourly nursing medical care. |
| (2) See reconciliation of GAAP to Non-GAAP measures. | (2) See reconciliation of GAAP to Non-GAAP measures. | (2) See reconciliation of GAAP to Non-GAAP measures. | (2) See reconciliation of GAAP to Non-GAAP measures. |

---

------

**Hospice**

---

| | | | |
|:---|:---|:---|:---|
| ***($ in millions)*** | **Q4** | **Q4** | **'25 vs. '24** |
| ***($ in millions)*** | **2025** | **2024** | **'25 vs. '24** |
| **Net service revenue** | **$63.6** | **$57.8** | **10.0%** |
| Cost of service | 30.5 | 27.6 | 10.5% |
| &nbsp;&nbsp;&nbsp;*Gross margin* | *52.0%* | *52.2%* |  |
| General and administrative expenses | 19.4 | 17.0 | 14.1% |
| Net income attributable to noncontrolling interests | **0.1** | (0.1) |  |
| **Segment Adjusted EBITDA**<sup>(1)</sup> | **$13.6** | **$13.3** | **2.3%** |
| &nbsp;&nbsp;*Segment Adjusted EBITDA margin*<sup>(1)</sup> | *21.4%* | *23.0%* |  |
| **Operational metrics (actual amounts)** |  |  |  |
| **Total admissions** | **3083** | 3059 | 0.8% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Same-store total admissions growth* |  |  | *(0.1)%* |
| **Patient days** | **377112** | 343063 | 9.9% |
| **Discharged average length of stay** | **110** | 110 | —% |
| **Average daily census**  | **4099** | 3729 | 9.9% |
| **Revenue per patient day** | **$168.7** | $168.6 | 0.1% |
| **Cost per patient day** | **$80.9** | $80.4 | 0.6% |
| (1) See reconciliation of GAAP to Non-GAAP measures. | (1) See reconciliation of GAAP to Non-GAAP measures. | (1) See reconciliation of GAAP to Non-GAAP measures. | (1) See reconciliation of GAAP to Non-GAAP measures. |

---

**ABOUT ENHABIT HOME HEALTH & HOSPICE**

Enhabit Home Health & Hospice (Enhabit, Inc.) is a leading national home health and hospice provider working to expand what's possible for patient care in the home. Enhabit's team of clinicians supports patients and their families where they are most comfortable, with a nationwide footprint spanning 249 home health locations and 117 hospice locations across 34 states. Enhabit leverages advanced technology and compassionate teams to deliver extraordinary patient care. For more information, visit <u>enhabit.com</u>.

**OTHER INFORMATION**

***Note regarding presentation and reconciliation of non-GAAP financial measures***

The financial data contained in this press release and supplemental information includes non-GAAP (generally accepted accounting principles (GAAP)) financial measures as defined in Regulation G under the Securities Exchange Act of 1934, including Adjusted EBITDA, Adjusted EBITDA margin, Segment Adjusted EBITDA, Segment Adjusted EBITDA Margin, Adjusted EPS, and Adjusted free cash flow. For 2025, the Company has modified its methodology of calculating Adjusted free cash flow to exclude the impact of unusual or nonrecurring items on cash income taxes and changes in working capital. The change was made to conform to the Adjusted free cash flow measure with the current definition used by management and the Board of Directors to manage cash flow and evaluate performance. Prior periods presented herein have been recast to conform with the new methodology.

The Company believes the non-GAAP financial measures are useful to investors because they facilitate evaluation of core business operating results over multiple periods unaffected by differences in unusual or nonrecurring items. See "Supplemental Non-GAAP Information" for reconciliations of the non-GAAP financial measures to the most directly comparable financial measures calculated and presented in accordance with GAAP. Additionally, our Form 10-K for the year ended December 31, 2025, provides further information regarding "unusual or nonrecurring items that are not typical of ongoing operations," a reconciliation item in our Adjusted EBITDA and Segment Adjusted EBITDA calculations. Such non-GAAP

------

financial measures exclude significant components in understanding and assessing financial performance and should therefore not be considered superior to, as a substitute for or alternative to the GAAP financial measures presented in this press release. The non-GAAP financial measures in the press release may differ from similar measures used by other companies.

***Note regarding presentation of same-store comparisons***

The Company uses "same-store" comparisons to explain the changes in certain performance metrics and line items within its financial statements. Same-store comparisons are calculated based on home health and hospice locations open throughout both the full current period and the immediately prior period presented. These comparisons include the financial results of market consolidation transactions in existing markets, as it is difficult to determine, with precision, the incremental impact of these transactions on the Company's results of operations.

------

**Enhabit, Inc. and Subsidiaries**

**Condensed Consolidated Statements of Income**

**(Unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Year Ended <br>December 31,** | **Year Ended <br>December 31,** |
| ***($ in millions, except per share data)*** | **2025** | **2024** | **2025** | **2024** |
| Net service revenue | $**270.4**  | $258.2  | $**1060.0**  | $1034.8  |
| Cost of service, excluding depreciation and amortization | **138.7**  | 133.1  | **540.2**  | 530.8  |
| General and administrative expenses | **112.3**  | 104.6  | **433.5**  | 425.9  |
| Depreciation and amortization | **5.0**  | 7.9  | **22.5**  | 31.5  |
| Impairment of goodwill | **44.7**  | 53.8  | **44.7**  | 161.7  |
| Impairment of intangible assets | **3.0**  | —  | **3.0**  | —  |
| &nbsp;&nbsp;&nbsp;Operating income (loss) | **(33.3)** | (41.2) | **16.1**  | (115.1) |
| Interest income | **0.2**  | —  | **0.2**  | —  |
| Interest expense and amortization of debt discounts and fees | **7.6**  | 10.1  | **34.0**  | 42.9  |
| Other (income) expense | **0.1**  | —  | **(19.1)** | —  |
| &nbsp;&nbsp;&nbsp;Income (loss) before income taxes and noncontrolling interests | **(40.8)** | (51.3) | **1.4**  | (158.0) |
| Provision for (benefit from) income taxes  | **(2.5)** | (5.5) | **4.0**  | (4.0) |
| &nbsp;&nbsp;&nbsp;**Net income (loss)** | **(38.3)** | (45.8) | **(2.6)** | (154.0) |
| Less: Net income attributable to noncontrolling interests | **0.4**  | 0.2  | **2.0**  | 2.2  |
| &nbsp;&nbsp;&nbsp;**Net income (loss) attributable to Enhabit, Inc.** | $**(38.7)** | $(46.0) | $**(4.6)** | $(156.2) |
| Weighted average common shares outstanding: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Basic | **50.7**  | 50.2  | **50.8**  | 50.2  |
| &nbsp;&nbsp;&nbsp;Diluted | **50.7**  | 50.2  | **50.8**  | 50.2  |
| **Earnings (loss) per common share:** |  |  |  |  |
| Basic earnings (loss) per share attributable to Enhabit, Inc. common stockholders | $**(0.76)** | $(0.92) | $**(0.09)** | $(3.11) |
| Diluted earnings (loss) per share attributable to Enhabit, Inc. common stockholders | $**(0.76)** | $(0.92) | $**(0.09)** | $(3.11) |

---

------

**Enhabit, Inc. and Subsidiaries**

**Condensed Consolidated Balance Sheets**

**(Unaudited)**

---

| | | |
|:---|:---|:---|
| ***($ in millions)*** | **December 31,<br>2025** | **December 31,<br>2024** |
| **Assets** | | |
| **Current assets:** | | |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | $**43.6**  | $28.4  |
| &nbsp;&nbsp;&nbsp;Restricted cash | **1.9**  | 1.9  |
| &nbsp;&nbsp;&nbsp;Accounts receivable, net of allowances | **144.0**  | 149.2  |
| &nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | **16.1**  | 13.2  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | **205.6**  | 192.7  |
| Property and equipment, net | **15.5**  | 17.7  |
| Operating lease right-of-use assets | **49.8**  | 52.8  |
| Goodwill | **855.3**  | 900.0  |
| Intangible assets, net | **38.5**  | 58.1  |
| Other long-term assets | **2.4**  | 4.7  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total assets** | $**1167.1**  | $1226.0  |
| **Liabilities and Stockholders' Equity** |  |  |
| **Current liabilities:** |  |  |
| &nbsp;&nbsp;&nbsp;Current portion of long-term debt | $**22.3**  | $22.8  |
| &nbsp;&nbsp;&nbsp;Current portion of operating lease liabilities | **12.6**  | 12.3  |
| &nbsp;&nbsp;&nbsp;Accounts payable | **9.2**  | 6.7  |
| &nbsp;&nbsp;&nbsp;Accrued payroll | **40.4**  | 37.1  |
| &nbsp;&nbsp;&nbsp;Other current liabilities | **41.8**  | 47.3  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | **126.3**  | 126.2  |
| Long-term debt, net of current portion | **426.0**  | 492.6  |
| Long-term operating lease liabilities, net of current portion | **39.1**  | 41.8  |
| Deferred income tax liabilities | **11.5**  | 11.5  |
| Other long-term liabilities | **0.1**  | —  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total liabilities** | **603.0**  | 672.1  |
| Commitments and contingencies |  |  |
| Redeemable noncontrolling interests | **5.0**  | 5.0  |
| **Stockholders' equity:** |  |  |
| &nbsp;&nbsp;&nbsp;Total Enhabit, Inc. stockholders' equity | **534.0**  | 523.5  |
| &nbsp;&nbsp;&nbsp;Noncontrolling interests | **25.1**  | 25.4  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total stockholders' equity** | **559.1**  | 548.9  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total liabilities and stockholders' equity** | $**1167.1**  | $1226.0  |

---

------

**Enhabit, Inc. and Subsidiaries**

**Condensed Consolidated Statements of Cash Flows**

**(Unaudited)**

---

| | | |
|:---|:---|:---|
| | **Year Ended <br>December 31,** | **Year Ended <br>December 31,** |
| ***($ in millions)*** | **2025** | **2024** |
| **Cash flows from operating activities:** |  |  |
| Net income (loss) | $**(2.6)** | $(154.0) |
| Adjustments to reconcile net loss to net cash provided by operating activities— |  |  |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization | **22.5**  | 31.5  |
| &nbsp;&nbsp;&nbsp;Amortization of debt related costs | **1.5**  | 1.5  |
| &nbsp;&nbsp;&nbsp;Gain on sale of investment | **(19.2)** | —  |
| &nbsp;&nbsp;&nbsp;Impairment of goodwill | **44.7**  | 161.7  |
| &nbsp;&nbsp;&nbsp;Impairment of intangible assets | **3.0**  | —  |
| &nbsp;&nbsp;&nbsp;Stock-based compensation | **16.6**  | 11.7  |
| &nbsp;&nbsp;&nbsp;Deferred income taxes | **—**  | (5.7) |
| &nbsp;&nbsp;&nbsp;Other, net | **0.4**  | (0.6) |
| &nbsp;&nbsp;&nbsp;Changes in assets and liabilities, net of acquisitions — |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net of allowances | **5.2**  | 15.5  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other assets  | **(2.3)** | 3.1  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | **2.6**  | (1.0) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued payroll | **3.7**  | (2.3) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other liabilities | **(5.4)** | (10.2) |
| &nbsp;&nbsp;&nbsp;**Net cash provided by operating activities** | **70.7**  | 51.2  |
| **Cash flows from investing activities:** |  |  |
| &nbsp;&nbsp;&nbsp;Purchases of property and equipment, including capitalized software costs | **(4.9)** | (3.8) |
| &nbsp;&nbsp;&nbsp;Proceeds from sale of investment | **21.0**  | —  |
| &nbsp;&nbsp;&nbsp;Other | **0.6**  | 1.4  |
| &nbsp;&nbsp;&nbsp;**Net cash provided by (used) in investing activities** | **16.7**  | (2.4) |
| **Cash flows from financing activities:** |  |  |
| &nbsp;&nbsp;&nbsp;Principal payments on term loan facility | **(20.0)** | (20.0) |
| &nbsp;&nbsp;&nbsp;Payments on revolving credit facility | **(45.0)** | (20.0) |
| &nbsp;&nbsp;&nbsp;Principal payments under finance lease obligations | **(2.7)** | (3.6) |
| &nbsp;&nbsp;&nbsp;Distributions paid to noncontrolling interests of consolidated affiliates | **(2.3)** | (3.7) |
| &nbsp;&nbsp;&nbsp;Other | **(2.2)** | (1.0) |
| &nbsp;&nbsp;&nbsp;**Net cash used in financing activities** | **(72.2)** | (48.3) |
| &nbsp;&nbsp;&nbsp;**Increase in cash, cash equivalents, and restricted cash** | **15.2**  | 0.5  |
| &nbsp;&nbsp;&nbsp;**Cash, cash equivalents, and restricted cash at beginning of year** | **30.3**  | 29.8  |
| &nbsp;&nbsp;&nbsp;**Cash, cash equivalents, and restricted cash at end of year** | $**45.5**  | $30.3  |

---

------

**Enhabit, Inc. and Subsidiaries**

**Supplemental Non-GAAP Information**

**(Unaudited)**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| (in millions except Diluted EPS amounts) | **Three Months Ended**<br>**December 31,** | **Three Months Ended**<br>**December 31,** | **Three Months Ended**<br>**December 31,** | **Three Months Ended**<br>**December 31,** | **Year Ended**<br>**December 31,** | **Year Ended**<br>**December 31,** | **Year Ended**<br>**December 31,** | **Year Ended**<br>**December 31,** |
| (in millions except Diluted EPS amounts) | **2025** | **2025** | **2024** | **2024** | **2025** | **2025** | **2024** | **2024** |
| (in millions except Diluted EPS amounts) | **Amount** | **Diluted EPS** | **Amount** | **Diluted EPS** | **Amount** | **Diluted EPS** | **Amount** | **Diluted EPS** |
| Net income (loss) attributable to Enhabit, Inc. | $**(38.7)** | $**(0.76)** | $(46.0) | (0.92) | $**(4.6)** | **(0.09)** | (156.2) | (3.11) |
| &nbsp;&nbsp;&nbsp;&nbsp;Impairment of goodwill | **39.0**  | **—**  | 44.0  |  | **39.0**  |  | 141.3  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Impairment of intangible assets | **2.3**  | **—**  | —  |  | **2.3**  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Gain on sale of investment and disposal of assets<sup>(1)</sup> | **—**  | **—**  | —  |  | **(14.7)** |  | —  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Unusual or nonrecurring items that are not typical of ongoing operations<sup>(2)</sup> | **1.7**  | **—**  | 1.1  |  | **5.8**  |  | 10.0  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Provision for (benefit from) income taxes<sup>(3)</sup> | **2.8**  | **—**  | 2.9  |  | **(0.3)** |  | 15.6  |  |
| Adjusted Net income (loss) attributable to Enhabit, Inc.  | $**7.1**  | $**0.14**  | $**2.0**  | **0.04**  | $**27.5**  | **0.53**  | **10.7**  | **0.21**  |
| Diluted weighted average common shares outstanding |  | **50.7**  |  | 50.2  |  | **50.8**  |  | 50.2  |
| Fully diluted weighted average common shares outstanding<sup>(4)</sup> |  | **52.2**  |  | 50.5  |  | **51.6**  |  | 50.4  |

---

(1)&nbsp;&nbsp;&nbsp;&nbsp;Gain on sale of investment in 2025 resulted from the sale of Medalogix investment.

(2)&nbsp;&nbsp;&nbsp;&nbsp;Unusual or nonrecurring items in the three months and year ended December 31, 2025 include costs associated with restructuring activities and severance, nonroutine litigation and third-party legal and advisory fees related to shareholder, non-shareholder and other matters, and merger and acquisition activities. Unusual or nonrecurring items in the three months ended December 31, 2024 include costs associated with nonroutine litigation and severance, and for the year ended December 31, 2024 also include costs associated with shareholder activism and the strategic review process that concluded in May 2024.

(3) &nbsp;&nbsp;&nbsp;&nbsp;Income tax adjustments include the effect of a valuation allowance recorded against a portion of our deferred tax assets and the effect of permanent book-tax differences attributable to stock-based compensation.

(4) &nbsp;&nbsp;&nbsp;&nbsp;Reflects diluted weighted average common shares outstanding plus potential common shares used for the calculation of adjusted diluted earnings per share.

------

**Enhabit, Inc. and Subsidiaries**

**Supplemental Non-GAAP Information**

**(Unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Reconciliation of Net Income (Loss) to Adjusted EBITDA** | **Reconciliation of Net Income (Loss) to Adjusted EBITDA** | **Reconciliation of Net Income (Loss) to Adjusted EBITDA** | **Reconciliation of Net Income (Loss) to Adjusted EBITDA** | **Reconciliation of Net Income (Loss) to Adjusted EBITDA** |
| | **Three Months Ended**<br>**December 31,** | **Three Months Ended**<br>**December 31,** | **Year Ended**<br>**December 31,** | **Year Ended**<br>**December 31,** |
| ***($ in millions)*** | **2025** | **2024** | **2025** | **2024** |
| **Net income (loss)** | $**(38.3)** | $**(45.8)** | $**(2.6)** | $**(154.0)** |
| Interest expense, net | 7.4  | 10.1  | 33.8  | 42.9  |
| (Benefit from) provision for income taxes | (2.5) | (5.5) | 4.0  | (4.0) |
| Depreciation and amortization | 5.0  | 7.9  | 22.5  | 31.5  |
| Loss (gain) on sale of investment and disposal of assets<sup>(1)</sup> | 0.1  | (0.2) | (19.1) | (0.7) |
| Impairment of goodwill | 44.7  | 53.8  | 44.7  | 161.7  |
| Stock-based compensation | 6.8  | 3.9  | 16.6  | 11.7  |
| Net income attributable to noncontrolling interests | (0.4) | (0.2) | (2.0) | (2.2) |
| Unusual or nonrecurring items that are not typical of ongoing operations<sup>(2)</sup> | 2.2  | 1.1  | 7.6  | 13.2  |
| &nbsp;&nbsp;&nbsp;**Adjusted EBITDA** | $**28.0**  | $**25.1**  | $**108.5**  | $**100.1**  |

---

(1)&nbsp;&nbsp;&nbsp;&nbsp;Gain on sale of investment in 2025 resulted from the sale of Medalogix investment.

(2)&nbsp;&nbsp;&nbsp;&nbsp;Unusual or nonrecurring items in the three months and year ended December 31, 2025 include costs associated with restructuring activities and severance, nonroutine litigation and third-party legal and advisory fees related to shareholder, non-shareholder and other matters, and merger and acquisition activities. Unusual or nonrecurring items in the three months ended December 31, 2024 include costs associated with nonroutine litigation and severance, and for the year ended December 31, 2024 also include costs associated with shareholder activism and the strategic review process that concluded in May 2024.

------

**Enhabit, Inc. and Subsidiaries**

**Supplemental Non-GAAP Information**

**(Unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Reconciliation of Income (Loss) Before Income Taxes And Noncontrolling Interests to Segment Adjusted EBITDA and Segment Adjusted EBITDA Margin** | **Reconciliation of Income (Loss) Before Income Taxes And Noncontrolling Interests to Segment Adjusted EBITDA and Segment Adjusted EBITDA Margin** | **Reconciliation of Income (Loss) Before Income Taxes And Noncontrolling Interests to Segment Adjusted EBITDA and Segment Adjusted EBITDA Margin** | **Reconciliation of Income (Loss) Before Income Taxes And Noncontrolling Interests to Segment Adjusted EBITDA and Segment Adjusted EBITDA Margin** | **Reconciliation of Income (Loss) Before Income Taxes And Noncontrolling Interests to Segment Adjusted EBITDA and Segment Adjusted EBITDA Margin** |
| | **Three Months Ended**<br>**December 31,** | **Three Months Ended**<br>**December 31,** | **Year Ended**<br>**December 31,** | **Year Ended**<br>**December 31,** |
| ***($ in millions)*** | **2025** | **2024** | **2025** | **2024** |
| **Income (loss) before income taxes and noncontrolling interests** | $**(40.8)** | $**(51.3)** | $**1.4**  | $**(158.0)** |
| Non-segment general and administrative expenses | 24.8  | 24.6  | 107.4  | 113.3  |
| Interest expense, net | 7.4  | 10.1  | 33.8  | 42.9  |
| Depreciation and amortization | 5.0  | 7.9  | 22.5  | 31.5  |
| Gain (loss) on sale of investment and disposal of assets<sup>(1)</sup> | 0.1  | —  | (19.1) | —  |
| Impairment of intangible assets | 3.0  | —  | 3.0  | —  |
| Impairment of goodwill | 44.7  | 53.8  | 44.7  | 161.7  |
| Stock-based compensation expense | 6.8  | 3.9  | 16.6  | 11.7  |
| Net income attributable to noncontrolling interests | (0.4) | (0.2) | (2.0) | (2.2) |
| &nbsp;&nbsp;&nbsp;**Total Segment Adjusted EBITDA** | $**50.6**  | $**48.8**  | $**208.3**  | $**200.9**  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Home Health** | **Home Health** | **Hospice** | **Hospice** | **Home Health** | **Home Health** | **Hospice** | **Hospice** |
| | **Three Months Ended<br>December 31,** | **Three Months Ended<br>December 31,** | **Three Months Ended<br>December 31,** | **Three Months Ended<br>December 31,** | **Year Ended**<br>**December 31,** | **Year Ended**<br>**December 31,** | **Year Ended**<br>**December 31,** | **Year Ended**<br>**December 31,** |
| ***($ in millions)*** | **2025** | **2024** | **2025** | **2024** | **2025** | **2024** | **2025** | **2024** |
| Net service revenue | $206.8 | $200.4 | $63.6 | $57.8 | $813.8 | $824.8 | $246.2 | $210.0 |
| Labor | 99.0 | 95.9 | 19.1 | 17.1 | 390.1 | 389.5 | 71.9 | 63.8 |
| Supplies and pharmacy | 2.3 | 2.4 | 5.6 | 5.1 | 9.5 | 9.9 | 21.8 | 19.4 |
| Travel | 5.4 | 5.4 | 1.4 | 1.3 | 20.8 | 21.8 | 5.1 | 4.7 |
| Other cost of service | 1.5 | 1.8 | 4.4 | 4.1 | 6.1 | 7.0 | 14.9 | 14.7 |
| Total cost of service, excluding depreciation and amortization | 108.2 | 105.5 | 30.5 | 27.6 | 426.5 | 428.2 | 113.7 | 102.6 |
| General and administrative salaries | 48.7 | 48.9 | 16.3 | 14.1 | 188.6 | 193.2 | 59.7 | 54.0 |
| Other general and administrative expenses<sup>(2)</sup> | 12.6 | 10.2 | 3.1 | 2.9 | 48.7 | 42.2 | 12.5 | 11.5 |
| Total general and administrative expenses | 61.3 | 59.1 | 19.4 | 17.0 | 237.3 | 235.4 | 72.2 | 65.5 |
| Net income attributable to noncontrolling interests | 0.3 | 0.3 | 0.1 | (0.1) | 1.5 | 1.8 | 0.5 | 0.4 |
| Segment Adjusted EBITDA | $37.0 | $35.5 | $13.6 | $13.3 | $148.5 | $159.4 | $59.8 | $41.5 |
| *Segment Adjusted EBITDA margin*<sup>(3)</sup> | *17.9* <br>*%* | *17.7* <br>*%* | *21.4* <br>*%* | *23.0* <br>*%* | *18.2* <br>*%* | *19.3* <br>*%* | *24.3* <br>*%* | *19.8* <br>*%* |

---

(1) Gain on sale of investment in 2025 resulted from the sale of Medalogix investment.

(2) Other general and administrative expenses are comprised of licensing fees and other individually insignificant fees for both the Home Health and Hospice segments.

(3) Segment Adjusted EBITDA margin is defined as the ratio of Segment Adjusted EBITDA to segment net service revenue.

------

**Enhabit, Inc. and Subsidiaries**

**Supplemental Information**

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Reconciliation of Net Cash Provided by Operating Activities to Adjusted Free Cash Flow** | **Reconciliation of Net Cash Provided by Operating Activities to Adjusted Free Cash Flow** | **Reconciliation of Net Cash Provided by Operating Activities to Adjusted Free Cash Flow** | **Reconciliation of Net Cash Provided by Operating Activities to Adjusted Free Cash Flow** | **Reconciliation of Net Cash Provided by Operating Activities to Adjusted Free Cash Flow** |
| | **Three Months Ended**<br>**December 31,** | **Three Months Ended**<br>**December 31,** | **Year Ended**<br>**December 31,** | **Year Ended**<br>**December 31,** |
| ***($ in millions)*** | **2025** | **2024** | **2025** | **2024** |
| **Net cash provided by operating activities** | $**4.3**  | $**(4.1)** | $**70.7**  | $**51.2**  |
| Unusual or nonrecurring items that are not typical of ongoing operations<sup>(1)</sup> | 3.5  | 1.1  | 10.1  | 13.2  |
| Capital expenditures for maintenance | (1.0) | (0.6) | (4.9) | (3.7) |
| Other working capital adjustments<sup>(2)</sup> | 0.4  | 0.3  | (2.4) | (3.5) |
| Distributions paid to noncontrolling interests of consolidated affiliates | (0.8) | (1.5) | (2.3) | (3.7) |
| **Adjusted free cash flow** | $**6.4**  | $**(4.8)** | $**71.2**  | $**53.5**  |

---

(1)&nbsp;&nbsp;&nbsp;&nbsp;Unusual or nonrecurring items in the three months and year ended December 31, 2025 include costs associated with restructuring activities and severance, nonroutine litigation and third-party legal and advisory fees related to shareholder, non-shareholder and other matters, and merger and acquisition activities. Unusual or nonrecurring items in the three months ended December 31, 2024 include costs associated with nonroutine litigation and severance, and for the year ended December 31, 2024 also include costs associated with shareholder activism and the strategic review process that concluded in May 2024.

(2)&nbsp;&nbsp;&nbsp;&nbsp;For 2025 and going forward, adjusted free cash flow will exclude the cash impact of unusual and nonrecurring items from both cash income tax payments (refunds), net and working capital and other. The 2024 calculations have been conformed to the current methodology, which has an impact of $1.0 million and less than $0.1 million for Q4 and the year to date period, respectively.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Reconciliation of Gross Margin to Adjusted EBITDA Margin** | **Reconciliation of Gross Margin to Adjusted EBITDA Margin** | **Reconciliation of Gross Margin to Adjusted EBITDA Margin** | **Reconciliation of Gross Margin to Adjusted EBITDA Margin** | **Reconciliation of Gross Margin to Adjusted EBITDA Margin** |
| | **Three Months Ended**<br>**December 31,** | **Three Months Ended**<br>**December 31,** | **Year Ended**<br>**December 31,** | **Year Ended**<br>**December 31,** |
|  | **2025** | **2024** | **2025** | **2024** |
| **Gross margin as a percentage of revenue** | **48.7%** | **48.5%** | **49.0%** | **48.7%** |
| General and administrative expenses | (41.5)% | (40.5)% | (40.9)% | (41.2)% |
| Stock-based compensation | 2.5% | 1.4% | 1.6% | 1.1% |
| Noncontrolling interests | (0.1)% | (0.1)% | (0.2)% | (0.2)% |
| Unusual or nonrecurring items that are not typical of ongoing operations<sup>(1)</sup> | 0.8% | 0.4% | 0.7% | 1.3% |
| **Adjusted EBITDA Margin** | **10.4%** | **9.7%** | **10.2%** | **9.7%** |

---

(1)&nbsp;&nbsp;&nbsp;&nbsp;Unusual or nonrecurring items in the three months and year ended December 31, 2025 include costs associated with restructuring activities and severance, nonroutine litigation and third-party legal and advisory fees related to shareholder, non-shareholder and other matters, and merger and acquisition activities. Unusual or nonrecurring items in the three months ended December 31, 2024 include costs associated with nonroutine litigation and severance, and for the year ended December 31, 2024 also include costs associated with shareholder activism and the strategic review process that concluded in May 2024.

------

**FORWARD-LOOKING STATEMENTS** 

This press release contains historical information, as well as forward-looking statements (within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act")) that involve known and unknown risks and relate to, among other things, future events, projections, financial guidance, legislative or regulatory developments, strategy or growth opportunities, our future financial performance, our projected business results, or our projected capital expenditures. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. In some cases, the reader can identify forward-looking statements by terminology such as "may," "will," "should," "could," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "targets," "potential," or "continue" or the negative of these terms or other comparable terminology. Any forward-looking statement speaks only as of the date of this presentation, and the Company undertakes no duty to publicly update or revise such forward-looking information, whether as a result of new information, future events, or otherwise. Such forward-looking statements are necessarily estimates based upon current information and involve a number of risks and uncertainties, many of which are beyond our control. Actual events or results may differ materially from the results anticipated in these forward-looking statements as a result of a variety of factors. While it is impossible to identify all such factors, factors which could cause actual events or results to differ materially from those estimated by the Company include, but are not limited to, disruption from the proposed Merger with patient, payor, provider, referral source, supplier or management and employee relationships; the occurrence of any event, change or other circumstances that could give rise to the termination of the Merger Agreement or the inability to complete the proposed transaction on the anticipated terms and timetable; the risk that certain regulatory approvals for the proposed Merger are delayed, are not obtained or are obtained subject to conditions that are not anticipated; the failure of the conditions to the proposed Merger to be satisfied; the costs related to the proposed transaction; the diversion of management time on Merger-related issues; the risk that termination fees may be payable by us in the event that the Merger Agreement is terminated under certain circumstances; reputational risk related to the proposed Merger; the risk of litigation or regulatory action related to the proposed Merger; our ability to execute on our strategic plans; regulatory and other developments impacting the markets for our services; changes in reimbursement rates; general economic conditions; changes in the episodic versus non-episodic mix of our payers, the case mix of our patients, and payment methodologies; our ability to attract and retain key management personnel and healthcare professionals; potential disruptions or breaches of our or our vendors', payers', and other contract counterparties' information systems; the outcome of litigation; quality performance and ratings; our ability to successfully complete and integrate de novo locations, acquisitions, investments, and joint ventures; our ability to successfully integrate technology in our operations; and our ability to control costs, particularly labor and employee benefit costs. Additional information regarding risks and factors that could cause actual results to differ materially from those expressed or implied by any forward-looking statement in this release are described in reports filed with the SEC, including our annual report on Form 10-K and subsequent quarterly reports on Form 10-Q, copies of which are available on the Company's website at http://investors.ehab.com.

**ADDITIONAL INFORMATION AND WHERE TO FIND IT**

This communication may be deemed to be solicitation material in respect of the transaction between the Company, Anchor Parent, LLC and Anchor Merger Sub, Inc. The Company expects to announce a special meeting of stockholders as soon as practicable to obtain stockholder approval of the proposed transaction. In connection with the transaction, the Company intends to file relevant materials with the SEC, including a proxy statement in preliminary and definitive form. INVESTORS ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH THE SEC, INCLUDING THE PROXY STATEMENT, CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE TRANSACTION AND THE PARTIES TO THE TRANSACTION. Investors may obtain a free copy of these materials (when they are available) and other documents filed by the Company with the SEC at the SEC's website at www.sec.gov, at the Company's

------

website at www.enhabit.com or by sending a written request to the Company in care of the Corporate Secretary, at Enhabit, Inc., 6688 N. Central Expressway, Suite 1300, Dallas, Texas 75206.

**PARTICIPANTS IN THE SOLICITATION**

The directors and executive officers of the Company, and other persons, may be deemed to be participants in the solicitation of proxies in respect of the transaction. Information regarding the Company's directors and executive officers is available in the Company's definitive proxy statement filed with the SEC on May 16, 2025 in connection with the Company's 2025 annual meeting of stockholders. This document can be obtained free of charge from the sources indicated above. Additional information regarding the interests of such participants in the solicitation of proxies in respect of the proposed transaction will be included in the proxy statement and other relevant materials to be filed with the SEC when they become available.

**Investor relations contact**

*Bob Okunski*

*investorrelations@ehab.com*

*469-860-6061*

**Media contact**

*Erin Volbeda* 

*media@ehab.com*

*972-338-5141*

## Exhibit 99.2

![](enhabit_earningsxslidesx001.jpg)

Fourth Quarter 2025 Supplemental Information March 4, 2026

------

![](enhabit_earningsxslidesx002.jpg)

Enhabit Home Health & Hospice 2 Disclaimers Forward looking statements This presentation contains historical information, as well as forward-looking statements (within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act")) that involve known and unknown risks and relate to, among other things, future events, projections, financial guidance, legislative or regulatory developments, strategy or growth opportunities, our future financial performance, our projected business results, or our projected capital expenditures. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. In some cases, the reader can identify forward-looking statements by terminology such as "may," "will," "should," "could," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "targets," "potential," or "continue" or the negative of these terms or other comparable terminology. Any forward-looking statement speaks only as of the date of this presentation, and the Company undertakes no duty to publicly update or revise such forward-looking information, whether as a result of new information, future events, or otherwise. Such forward-looking statements are necessarily estimates based upon current information and involve a number of risks and uncertainties, many of which are beyond our control. Actual events or results may differ materially from the results anticipated in these forward-looking statements as a result of a variety of factors. While it is impossible to identify all such factors, factors which could cause actual events or results to differ materially from those estimated by the Company include, but are not limited to, disruption from the proposed acquisition by Kinderhook Industries, LLC (the "Merger") with patient, payor, provider, referral source, supplier or management and employee relationships; the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement relating to the Merger (the "Merger Agreement") or the inability to complete the proposed transaction on the anticipated terms and timetable; the risk that certain regulatory approvals for the proposed Merger are delayed, are not obtained or are obtained subject to conditions that are not anticipated; the failure of the conditions to the proposed Merger to be satisfied; the costs related to the proposed transaction; the diversion of management time on Merger-related issues; the risk that termination fees may be payable by us in the event that the Merger Agreement is terminated under certain circumstances; reputational risk related to the proposed Merger; the risk of litigation or regulatory action related to the proposed Merger; our ability to execute on our strategic plans; regulatory and other developments impacting the markets for our services; changes in reimbursement rates; general economic conditions; changes in the episodic versus non-episodic mix of our payers, the case mix of our patients, and payment methodologies; our ability to attract and retain key management personnel and healthcare professionals; potential disruptions or breaches of our or our vendors', payers', and other contract counterparties' information systems; the outcome of litigation; quality performance and ratings; our ability to successfully complete and integrate de novo locations, acquisitions, investments, and joint ventures; our ability to successfully integrate technology in our operations; and our ability to control costs, particularly labor and employee benefit costs. Additional information regarding risks and factors that could cause actual results to differ materially from those expressed or implied by any forward-looking statement in this presentation are described in reports filed with the SEC, including our annual report on Form 10-K and subsequent quarterly reports on Form 10-Q, copies of which are available on the Company's website at http://investors.ehab.com. Note regarding presentation of non-GAAP financial measures This presentation includes certain "non-GAAP financial measures" as defined in Regulation G under the Exchange Act, including Adjusted EBITDA, Adjusted EBITDA margin, Segment Adjusted EBITDA, Segment Adjusted EBITDA margin, Adjusted earnings per share, and Adjusted free cash flow. For 2025, the Company has modified its methodology of calculating Adjusted free cash flow to exclude the impact of unusual or nonrecurring items on cash income taxes and changes in working capital. The change was made to conform to the Adjusted free cash flow measure with the current definition used by management and the Board of Directors to manage cash flow and evaluate performance. Prior periods presented herein have been recast to conform with the new methodology. The Company believes the non-GAAP financial measures are useful to investors because they facilitate evaluation of core business operating results over multiple periods unaffected by differences in unusual or nonrecurring items. Reconciliations of these non-GAAP financial measures to the most directly comparable financial measures calculated in accordance with GAAP are presented at the end of this presentation. Our Form 8-K, filed with the SEC as of the date of this presentation, provides further explanation and disclosure regarding Enhabit's use of non-GAAP financial measures and should be read in conjunction with this supplemental information. Additionally, our Form 10-K for the three months and year ended December 31, 2025, provides further information regarding "unusual or nonrecurring items that are not typical of ongoing operations," a reconciliation item in our Adjusted EBITDA calculation. Note regarding presentation of same-store comparisons The Company uses "same-store" comparisons to explain the changes in certain performance metrics and line items within its financial statements. Same-store comparisons are calculated based on home health and hospice locations open throughout both the full current period and the immediately prior period presented. These comparisons include the financial results of market consolidation transactions in existing markets, as it is difficult to determine, with precision, the incremental impact of these transactions on the Company's results of operations.

------

![](enhabit_earningsxslidesx003.jpg)

Contents Overview 4 2025 Year in Review 5 Quarterly Results at a Glance 6 2026 Priorities 7 Consolidated Results 8 Clinical Expertise and High-Quality Outcomes 9 Home Health Segment KPI Performance 10-11 Hospice Segment KPI Performance 12-13 Balance Sheet 14 Adjusted Free Cash Flow Assumptions 15 Appendix A: Supplemental Financial and Operational Metrics 16-27 Appendix B: Reconciliations to GAAP 28-35

------

![](enhabit_earningsxslidesx004.jpg)

Enhabit Home Health & Hospice 4 Overview 111 Hospice locations co-located with Home Health locations(1) Home Health Locations Hospice Locations Home Health & Hospice State Home Health Only State (1) As of December 31, 2025 - due to scale, not all locations can be represented by locational markers 117 Hospice Locations(1) 249 Home Health Locations(1) We are a leading provider of home health and hospice services that strives to provide superior, cost-effective care where patients prefer it: in their homes For over 25 years, we've provided care with high-quality outcomes, becoming a trusted partner of health systems, payers and other risk-bearing entities We operate nationally across 34 states with approximately 10,800 employees We foster an award-winning culture that is a strategic advantage in attracting and retaining talent and a main contributor to our continued success 10 Home Health (3) and Hospice (7) de novo locations opened in 2025 Hospice Only State

------

![](enhabit_earningsxslidesx005.jpg)

Enhabit Home Health & Hospice 5 2025 Execution - Return to Growth / Strengthened Balance Sheet Well Positioned for Continued Success in 2026 Reconciliations to GAAP provided in Appendix B Consistent Growth Revenues +2.4% and Adj. EBITDA +8.4% FY Improved Leverage and Free Cash Flow Provides Ability to Accelerate Growth via De Novo & Strategic M&A

------

![](enhabit_earningsxslidesx006.jpg)

Enhabit Home Health & Hospice 6 Improved financial performance • Total net service revenue rose to $270.4M, an increase of 2.6% sequentially and 4.7% year over year. • Net loss attributable to Enhabit, Inc. of $38.7M.(1) • Adjusted EBITDA increased 11.6% to $28.0M, rose 3.7% sequentially. • Reduced bank debt by $15 million in Q4; exited Q4 with 3.7x leverage ratio. Quarterly Results at a Glance Total admissions increased 7.3% • Net service revenue rose 3.2% to $206.8M, Adjusted EBITDA increased 4.2%. • ADC growth of 6.4%, continued stabilization in Medicare ADC decline, down 1.7% sequentially. • Non-Medicare admissions increased 16.0%, revenue per visit rose 7.5%. • Cost per patient day improved 3.5% on better staff optimization. Average daily census grew 9.9% • ADC increased sequentially every quarter since Q1 2024. • Admissions increased 0.8% or 2.6% when normalized for branches closed in 2025. • Net service revenue increased by 10.0% to $63.6M. Adjusted EBITDA increased 2.3%. • Cost per patient day increased 0.6% year over year. Home Health Hospice Consolidated \*All percentages based on year over year comparison between fourth quarter 2025 and the fourth quarter of 2024 operating results unless otherwise indicated (1) Includes $(47.7)M impairment to goodwill and intangible assets Reconciliations to GAAP provided in Appendix B

------

![](enhabit_earningsxslidesx007.jpg)

Enhabit Home Health & Hospice 7 2026 Priorities for Success • Increase patient census • Optimize VPE to enable capacity expansion • Open new de novo locations - 3-6 home health / 9-12 hospice • Strategic M&A opportunities - targeting $25-$50M investment • Continue to de-lever balance sheet • Optimize payer mix • Reduce home health cost per patient day • Reduce hospice cost per patient day • Value-based performance • Patient and family experience • Home health hospital readmission rates • Hospice visits in the last days of life • Engagement • Retention • Build clinical capacity to support growth objectives • Business development direct selling headcount • Leadership development

------

![](enhabit_earningsxslidesx008.jpg)

Enhabit Home Health & Hospice 8 Consolidated Results Q4 '25 vs. '24($ in millions, except per share data) 2025 2024 Home Health net service revenue $206.8 $200.4 3.2 % Hospice net service revenue 63.6 57.8 10.0 % Total net service revenue $270.4 $258.2 4.7 % % of revenue % of revenue Cost of service 51.3 % $138.7 51.5 % $133.1 4.2 % Gross margin 48.7 % 131.7 48.5 % 125.1 5.3 % General and administrative expenses 38.2 % 103.2 38.7 % 99.8 3.4 % Total operating expenses 89.5 % $241.9 90.2 % $232.9 3.9 % Other income $(0.1) $— Net income attributable to noncontrolling interests $0.4 $0.2 Adjusted EBITDA(1) $28.0 $25.1 11.6 % Adjusted EBITDA margin(1) 10.4 % 9.7 % Impairment of goodwill $44.7 $53.8 (16.9)% Impairment of intangible assets $3.0 $— N/A Net income (loss) attributable to Enhabit, Inc. $(38.7) $(46.0) 15.9 % Reported diluted EPS $(0.76) $(0.92) (17.4) % Adjusted diluted EPS(1) $0.14 $0.04 250.0 % General and administrative expenses in the above table exclude: Loss (gain) on disposal of assets $0.1 $(0.2) Stock-based compensation expense $6.8 $3.9 Unusual or nonrecurring items that are not typical of ongoing operations(2) $2.2 $1.1 (1) See Appendix B for reconciliation of GAAP to Non-GAAP measures. (2) Unusual or nonrecurring items in the three months ended December 31, 2025 include costs associated with restructuring activities and severance, nonroutine litigation and third-party legal and advisory fees related to shareholder, non-shareholder and other matters, and merger and acquisition activities; in the three months ended December 31, 2024, they include costs associated with nonroutine litigation and severance.

------

![](enhabit_earningsxslidesx009.jpg)

Enhabit Home Health & Hospice 9 Clinical Expertise and High-Quality Outcomes Enhabit National Average % Better Than Average HHCAHPS Star Rating1 3.9 3.7 5.4% 99% of our home health agencies are 3 Stars or higher; 75% are 4 Stars or higher2 30-Day Hospital Readmission Rate2 14.4% 18.0% 20.0% % of patients readmitted to an acute care hospital within 30 days of start of care or resumption of care Hospice Visits in Last Days of Life3 63.8% 48.3% 32.1% % of patients who received in person visits from RN or medical social worker on at least two out of the final three days of the patient's life CAHPS Hospice Star Rating4 3.9 3.6 8.3% >90% of our hospice agencies are 3 Stars or higher; >60% are 4 Stars or higher Standardized Protocols Motivated Clinicians Disciplined Use of Technology Superior Performance ü ü ü (1) Home Health Care Consumer Assessment of Healthcare Providers (HHCAHPS) Patient Survey Star Ratings as of January 14, 2026 for dates of service October 1, 2024 to June 30, 2025 (2) Research Institute for Home Care 2024 Chartbook (data from Medicare Standard Analytics Files for CY 2023), Enhabit data is as of Q4 2025 (3) Provider data from data.cms.gov/provider-data as of November 26, 2025 for dates of service January 1, 2023 to December 31, 2024 (4) Consumer Assessment of Healthcare Providers (CAHPS) Hospice Survey Star Ratings as of November 26, 2025 for dates of service October 1, 2022 to September 31, 2024 ü

------

![](enhabit_earningsxslidesx010.jpg)

Enhabit Home Health & Hospice 10 Home Health Q4 Revenue KPI Performance Home health returns to growth, as total revenue increased approximately $6.3 million, or 3.1% sequentially, and 3.2% year over year Q4 home health sequential revenue drivers: • Volume: increase in average daily census of 2.1%, primarily on higher admission volumes • Unit Revenue: increase in revenue per patient day of 1.0% reflects improved non-Medicare unit revenue rate partially offset by payer mix shift ADC growth to prior year of 6.4% driven primarily by admission growth of 7.3% and 8.1% when normalizing for closed branches ADC growth sequentially by 2.1% with significant growth in non-Medicare volumes as we saw full recovery of the temporary impact of negotiation with national payer in Q3 Revenue per patient day of $53, improvement of 1.0% sequentially and lower 2.9% year over year primarily on payer mix shift Continued successful execution on strategy to stem Medicare ADC rate of decline to prior year by more than half with Medicare ADC decline of 4.0% in the quarter vs. prior year and decline of 3.2% when normalizing for closed branches; compares to a decline of 11.6% to prior year in the corresponding 2024 period

------

![](enhabit_earningsxslidesx011.jpg)

Enhabit Home Health & Hospice 11 Home Health Q4 Profitability KPI Performance Gross margin of 47.7%, improvement of 140bps sequentially and higher by 30bps year over year Q4 Home Health sequential Gross Margin drivers: • Unit Revenue: improvement of 1% on an increase in revenue per patient day of 1.0% sequentially reflects improved non-Medicare unit revenue rate on improved collection rates in the quarter partially offset by payer mix shift • Unit Cost: improvement sequentially of 1.4% on improved clinical staff productivity helping to offset Q4 2025 average merit increase of 3% Reconciliations to GAAP provided in Appendix B Q4 Home Health Adjusted EBITDA of $37.0 million reflects growth of $3.1 million, or 9.1% sequentially, and $1.5 million or 4.2% year over year Sequential Adjusted EBITDA variance walk: • Volume increased Adjusted EBITDA $2.0 million on higher average daily census and unit revenues • Rate/Yield increased Adjusted EBITDA $3.8 million with Gross Margin as a % of revenue higher 140bps on improved cost per patient day, volumes and unit revenue • Sales and Ops back-office G&A costs decreased Adjusted EBITDA ($2.7) million primarily on merit increase effective Oct 1 and increased FTE to support higher volumes, offset by reduction in year end incentive bonus Cost per patient day of $27.8 improved 1.4% sequentially and improved 3.5% year over year Sequential impact of Q4 2025 average merit increase of 3% (effective October 1) largely offset by clinical staff productivity improvements enabling increased patient caseloads

------

![](enhabit_earningsxslidesx012.jpg)

Enhabit Home Health & Hospice 12 Hospice Q4 Revenue KPI Performance Revenue per patient day increased 0.3% sequentially and 0.1% year over year reflects CMS Medicare reimbursement rate increase effective October 2025, offset by favorable non-recurring collections rate benefit in prior year Continued growth in Average Daily Census with sequential growth of 0.5% and to prior year of 9.9% with discharged average length of stay flat at 110 days to prior year Admissions flat sequentially, increasing 0.8% year over year; normalized for closed branches year over year growth of 2.6% Hospice revenue increased $0.5 million or 0.8% sequentially and $5.8 million or 10.0% year over year Hospice sequential revenue drivers: • Volume: increase in average daily census of 0.5% • Unit Revenue: increase in revenue per patient day of 0.3%

------

![](enhabit_earningsxslidesx013.jpg)

Enhabit Home Health & Hospice 13 Hospice Q4 Profitability KPI Performance Gross margin of 52.0%, decreasing 350bps sequentially and in line year over year Q4 hospice sequential revenue drivers: • Unit Revenue: +0.3% sequentially with combination of CMS rate increase partially offset by favorable non-recurring collections rate benefit in prior period • Unit Cost: +8.0% sequentially primarily on Q4 average merit increase of 3% and lower productivity due to ramp of new hire clinical staff for future volume growth Hospice Adjusted EBITDA of $13.6 million decreased $3.6 million or 20.9% sequentially, and increased 2.3% year over year Sequential Adjusted EBITDA variance walk: • Volume increased Adjusted EBITDA $0.2 million on growth in ADC of 0.5% • Rate/Yield decreased Adjusted EBITDA ($2.0) million with higher per patient day costs compressing margins slightly offset by higher unit revenues • Sales and Ops back-office G&A costs decreased EBITDA ($1.8) million on increased sales related investment costs to support future volume growth Cost per patient day increased sequentially to $80.9 while improving to prior year by 0.6% Q4 2025 average merit increase of 3% effective October 1 Merit increase and lower productivity on ramping new hire clinical staff were primary drivers in sequential increase in cost per patient day Merit increase more than offset by productivity improvements are drivers to year over year improvement Reconciliations to GAAP provided in Appendix B

------

![](enhabit_earningsxslidesx014.jpg)

Enhabit Home Health & Hospice 14 Balance Sheet Strength Continues to Improve Leverage ratio decrease from Q4 2023 largely due to bank debt reduction during this period Leverage Ratio Improved 1.7 Turns $125M Reduction in Total Debt(1) Since Q4 2023 8 straight quarters of prepayments inclusive of $20M of voluntary prepayment in Q1 2026(2) (1) Total debt is defined as summation of advances under revolving credit and term loan facilities (2) In February 2026, the Company entered into an amended and restated credit agreement, please see the 8-K filed on March 2, 2026 for additional information ~$22M of Lower Annualized Cash Interest Expense Q4 2025 Annualized Cash Interest Expense reduced ~$22M from Q4 2023, fueling deleveraging efforts $ in millions $ in millions

------

![](enhabit_earningsxslidesx015.jpg)

Enhabit Home Health & Hospice 15 Adjusted Free Cash Flow Assumptions ($ in millions) Certain cash flow items 2024 Full Year 2025 Full Year Adjusted EBITDA(1) $100.1 $108.5 Less: Cash interest expense(2) 42.7 32.4 Cash income tax payments (refunds), net(3) 1.9 0.8 Working capital and other(3)(4) (1.8) (0.8) Maintenance capital expenditures 3.8 4.9 Adjusted free cash flow $53.5 $71.2 (1) See Appendix B for reconciliation of GAAP to Non-GAAP measures. (2) Cash interest payments in 2025 are based on current interest rate forward curves. (3) For 2025 and going forward, adjusted free cash flow will exclude the cash impact of unusual and nonrecurring items from both cash income tax payments, net, and working capital and other. The 2024 calculations have been conformed to the current methodology, which has an impact of less than $0.1 million for the full year. (4) The change in working capital for YTD 2025 was primarily the result of lower accounts receivable and the timing of payroll. ($ in millions) Growth in Core Business 2024 Full Year 2025 Full Year De novos $1.2 $0.8 Debt repayments, net $40.0 $65.0 Adjusted Free Cash Flow Uses and Assumptions

------

![](enhabit_earningsxslidesx016.jpg)

Enhabit Home Health & Hospice 16 Appendix A

------

![](enhabit_earningsxslidesx017.jpg)

Enhabit Home Health & Hospice 17 Debt & Liquidity Metrics ($ in millions) December 31, 2025 December 31, 2024 $400 million term loan facility, due 2027 (1)(2) $328.7 $348.0 Advances under revolving credit facility, due 2027(1) 115.0 160.0 Finance lease obligations 4.6 7.4 Total debt $448.3 $515.4 Less: Cash and cash equivalents 43.6 28.4 Net debt $404.7 $487.0 Net debt to Adjusted EBITDA(3) 3.7 x 4.9 x Trailing twelve-month Adjusted EBITDA(4) $108.5 $100.1 Available liquidity(5) $136.1 $79.8 (1) The Q4 2025 weighted average interest rate was 6.12% (SOFR + credit spread adjustment + 250 bps). (2) In October 2022, Enhabit entered into an interest rate swap to fix the rate on the $200 million of its term loan. The swap fixed the SOFR component of the interest rate at 4.3%, and matured in October 2025. (3) Defined as the ratio of Net debt to Trailing twelve-month Adjusted EBITDA. (4) See Appendix B for reconciliation of GAAP to Non-GAAP measures. (5) Defined as of December 31, 2025 as our $220.0 million revolving credit facility, less $115.0 million in advances, less $12.5 million in standby letters of credit plus cash and cash equivalents of $43.6 million, and as December 31, 2024 as our $220.0 million revolving credit facility, less $160.0 million in advances, less $86.0 million in standby letters of credit plus cash and cash equivalents of $28.4 million.

------

![](enhabit_earningsxslidesx018.jpg)

Enhabit Home Health & Hospice 18 Consolidated Adjusted EBITDA ($ in millions) Q4 2025 % of Consolidated Revenue Q4 2024 % of Consolidated Revenue Home Health Segment Adjusted EBITDA $37.0 $35.5 Hospice Segment Adjusted EBITDA 13.6 13.3 Home office general and administrative expenses (22.6) 8.4 % (23.7) 9.2 % Consolidated Adjusted EBITDA(1) $28.0 $25.1 Home office general and administrative expenses in the above table exclude: Loss (gain) on disposal of assets $0.1 $(0.2) Stock-based compensation expense $6.8 $3.9 Unusual or nonrecurring items that are not typical of ongoing operations(2) $2.2 $1.1 (1) See Appendix B for reconciliation of GAAP to Non-GAAP measures. (2) Unusual or nonrecurring items in the three months ended December 31, 2025 include costs associated with restructuring activities and severance, nonroutine litigation and third-party legal and advisory fees related to shareholder, non-shareholder and other matters, and merger and acquisition activities; in the three months ended December 31, 2024, they include costs associated with nonroutine litigation and severance.

------

![](enhabit_earningsxslidesx019.jpg)

Enhabit Home Health & Hospice 19 Home Health Segment ($ in millions) Q4 '25 vs. '242025 2024 Net service revenue: Medicare $111.6 $117.3 (4.9) % Non-Medicare 93.4 80.8 15.6 % Private duty(1) 1.8 2.3 (21.7) % Home Health net service revenue 206.8 200.4 3.2 % Cost of service 108.2 105.5 2.6 % Gross margin 47.7 % 47.4 % General and administrative expenses 61.3 59.1 3.7 % Net income attributable to noncontrolling interests 0.3 0.3 — % Segment Adjusted EBITDA(2) $37.0 $35.5 4.2 % Segment Adjusted EBITDA margin(2) 17.9 % 17.7 % Operational metrics (actual amounts) Medicare: Admissions 22,196 23,121 (4.0) % Recertifications 15,203 16,300 (6.7) % Completed episodes 38,077 39,104 (2.6) % Average daily census 19,030 19,818 (4.0) % Visits 490,281 560,002 (12.5) % Visits per episode 12.9 14.3 (9.8) % Revenue per episode $2,931 $3,000 (2.3) % Non-Medicare: Admissions 34,582 29,810 16.0 % Recertifications 14,840 13,541 9.6 % Average daily census 23,294 19,968 16.7 % Visits 574,023 533,618 7.6 % Total: Admissions 56,778 52,931 7.3 % Same-store total admissions growth 7.2 % Recertifications 30,043 29,841 0.7 % Same-store total recertifications growth 0.7 % Average daily census 42,324 39,786 6.4 % Visits 1,064,304 1,093,620 (2.7) % Visits per episode 12.5 13.9 (10.1) % Cost per visit $101.7 $95.0 7.1 % Revenue per patient day $53.1 $54.7 (2.9) % Cost per patient day $27.8 $28.8 (3.5) % (1) Private duty represents long-term comprehensive hourly nursing medical care. (2) See Appendix B for reconciliation of GAAP to Non-GAAP measures.

------

![](enhabit_earningsxslidesx020.jpg)

Enhabit Home Health & Hospice 20 Home Health Operational Metrics (net service revenue $ in millions) Q1 2024 Q2 2024 Q3 2024 Q4 2024 FY 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 FY 2025 Medicare $128.3 $121.7 $117.3 $117.3 $484.6 $114.2 $116.0 $113.4 $111.6 $455.2 Non-Medicare 82.6 86.3 81.5 80.8 331.2 84.4 87.8 85.2 93.4 350.8 Private duty(1) 2.3 2.2 2.2 2.3 9.0 2.0 2.1 1.9 1.8 7.8 Home Health net service revenue $213.2 $210.2 $201.0 $200.4 $824.8 $200.6 $205.9 $200.5 $206.8 $813.8 (actual amounts) Medicare: Admissions 25,944 24,015 23,422 23,121 96,502 24,044 23,138 22,225 22,196 91,603 Recertifications 17,652 16,639 16,101 16,300 66,692 15,734 15,860 15,890 15,203 62,687 Completed episodes 43,171 41,620 38,866 39,104 162,761 38,266 38,818 37,875 38,077 153,036 Average daily census 21,713 20,628 19,630 19,818 20,447 20,110 19,931 19,361 19,030 19,605 Visits 632,047 597,742 561,525 560,002 2,351,316 547,690 546,877 530,078 490,281 2,114,926 Visits per episode 14.6 14.4 14.4 14.3 14.4 14.3 14.1 14.0 12.9 13.8 Revenue per episode $2,972 $2,924 $3,018 $3,000 $2,977 $2,984 $2,988 $2,994 $2,931 $2,974 Non-Medicare: Admissions 30,881 30,209 29,950 29,810 120,850 33,178 31,774 33,065 34,582 132,599 Recertifications 13,489 14,587 14,112 13,541 55,729 13,133 14,532 14,410 14,840 56,915 Average daily census 20,555 21,281 20,357 19,968 20,540 21,126 22,191 22,090 23,294 22,181 Visits 571,289 581,326 552,815 533,618 2,239,048 542,526 570,424 562,122 574,023 2,249,095 Total: Admissions 56,825 54,224 53,372 52,931 217,352 57,222 54,912 55,290 56,778 224,202 Recertifications 31,141 31,226 30,213 29,841 122,421 28,867 30,392 30,300 30,043 119,602 Average daily census 42,268 41,909 39,987 39,786 40,987 41,236 42,122 41,451 42,324 41,785 Visits 1,203,336 1,179,068 1,114,340 1,093,620 4,590,364 1,090,216 1,117,301 1,092,200 1,064,304 4,364,021 Visits per episode 14.9 14.0 14.1 13.9 14.2 13.9 13.7 13.4 12.5 13.4 Cost per visit $90.0 $89.0 $93.7 $95.0 $93.0 $93.5 $94.7 $97.4 $101.7 $97.7 Revenue per patient day $55.4 $55.1 $54.6 $54.7 $55.0 $54.1 $53.7 $52.6 $53.1 $53.4 Cost per patient day $28.6 $28.0 $28.8 $28.8 $28.5 $27.9 $28.0 $28.2 $27.8 $28.0 (1) Private duty represents long-term comprehensive hourly nursing medical care.

------

![](enhabit_earningsxslidesx021.jpg)

Enhabit Home Health & Hospice 21 Hospice Segment ($ in millions) Q4 '25 vs. '242025 2024 Net service revenue $63.6 $57.8 10.0 % Cost of service 30.5 27.6 10.5 % Gross margin 52.0 % 52.2 % General and administrative expenses 19.4 17.0 14.1 % Net income attributable to noncontrolling interests 0.1 (0.1) (200.0) % Segment Adjusted EBITDA(1) $13.6 $13.3 2.3 % Segment Adjusted EBITDA margin(1) 21.4 % 23.0 % Operational metrics (actual amounts) Total admissions 3,083 3,059 0.8 % Same-store total admissions growth (0.1) % Patient days 377,112 343,063 9.9 % Discharged average length of stay 110 110 — % Average daily census 4,099 3,729 9.9 % Revenue per patient day $168.7 $168.6 0.1 % Cost per patient day $80.9 $80.4 0.6 % (1) See Appendix B for reconciliation of GAAP to Non-GAAP measures.

------

![](enhabit_earningsxslidesx022.jpg)

Enhabit Home Health & Hospice 22 Hospice Operational Metrics (net service revenue $ in millions) Q1 2024 Q2 2024 Q3 2024 Q4 2024 FY 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 FY 2025 Hospice net service revenue $49.2 $50.4 $52.6 $57.8 $210.0 $59.3 $60.2 $63.1 $63.6 $246.2 (actual amounts) Total admissions 3,032 2,888 3,046 3,059 12,025 3,274 3,140 3,089 3,083 12,586 Patient days 308,542 320,026 333,247 343,063 1,304,878 342,784 359,486 375,039 377,112 1,454,421 Discharged average length of stay 104 108 100 110 105 101 103 101 110 104 Average daily census 3,391 3,517 3,622 3,729 3,565 3,809 3,950 4,077 4,099 3,985 Revenue per patient day $159.6 $157.5 $157.7 $168.6 $160.9 $173.0 $167.5 $168.2 $168.7 $169.3 Cost per patient day $78.8 $77.9 $77.3 $80.4 $78.6 $78.2 $78.7 $74.9 $80.9 $78.2

------

![](enhabit_earningsxslidesx023.jpg)

Enhabit Home Health & Hospice 23 Consolidated Results – YTD 2025 ($ in millions, except per share data) Year-To-Date '25 vs. '242025 2024 Home Health net service revenue $813.8 $824.8 (1.3) % Hospice net service revenue 246.2 210.0 17.2 % Total net service revenue $1,060.0 $1,034.8 2.4 % % of Revenue % of Revenue Cost of service 51.0 % 540.2 51.3 % 530.8 1.8 % Gross margin 49.0 % 519.8 48.7 % 504.0 3.1 % General and administrative expenses 40.4 % 428.4 38.8 % 401.7 6.6 % Total operating expenses 91.4 % 968.6 90.1 % 932.5 3.9 % Other income 19.1 — Net income attributable to noncontrolling interests 2.0 2.2 Adjusted EBITDA $108.5 $100.1 8.4 % Adjusted EBITDA margin 10.2 % 9.7 % Impairment of goodwill $44.7 $161.7 (72.4) % Impairment of intangible assets $3.0 $— N/A Net income (loss) attributable to Enhabit, Inc. $(4.6) $(156.2) 97.1 % Reported diluted EPS $(0.09) $(3.11) 97.1 % Adjusted diluted EPS(1) $0.53 $0.21 152.4 % General and administrative expenses in the above table exclude: Loss (gain) on disposal of assets $(19.1) $(0.7) Stock-based compensation expense $16.6 $11.7 Unusual or nonrecurring items that are not typical of ongoing operations(2) $7.6 $13.2 (1) See Appendix B for reconciliation of GAAP to Non-GAAP measures. (2) Unusual or nonrecurring items in the year ended December 31, 2025 include costs associated with restructuring activities and severance, nonroutine litigation and third-party legal and advisory fees related to shareholder, non-shareholder and other matters, and merger and acquisition activities, and in the year ended December 31, 2024 they also include costs associated with shareholder activism, the strategic review process that concluded in May 2024, nonroutine litigation, and severance.

------

![](enhabit_earningsxslidesx024.jpg)

Enhabit Home Health & Hospice 24 Home Health Segment Results – YTD 2025 ($ in millions) Year-To-Date '25 vs. '242025 2024 Net service revenue: Medicare $455.2 $484.6 (6.1) % Non-Medicare 350.8 331.2 5.9 % Private duty(1) 7.8 9.0 (13.3) % Home Health net service revenue 813.8 824.8 (1.3) % Cost of service 426.5 428.2 (0.4) % Gross margin 47.6 % 48.1 % General and administrative expenses 237.3 235.4 0.8 % Other income — — N/A Net income attributable to noncontrolling interests 1.5 1.8 (16.7) % Segment Adjusted EBITDA(2) $148.5 $159.4 (6.8) % Segment Adjusted EBITDA margin(2) 18.2 % 19.3 % Operational metrics (actual amounts) Medicare: Admissions 91,603 96,502 (5.1) % Recertifications 62,687 66,692 (6.0) % Completed episodes 153,036 162,761 (6.0) % Average daily census 19,605 20,447 (4.1) % Visits 2,114,926 2,351,316 (10.1) % Visits per episode 13.8 14.4 (4.2) % Revenue per episode $2,974 $2,977 (0.1) % Non-Medicare: Admissions 132,599 120,850 9.7 % Recertifications 56,915 55,729 2.1 % Average daily census 22,181 20,540 8.0 % Visits 2,249,095 2,239,048 0.4 % Total: Admissions 224,202 217,352 3.2 % Same-store total admissions growth 4.5 % Recertifications 119,602 122,421 (2.3) % Same-store total recertifications growth (5.9) % Average daily census 41,786 40,987 1.9 % Visits 4,364,021 4,590,364 (4.9) % Visits per episode 13.4 14.2 (5.6) % Cost per visit $97.7 $93.0 5.1 % Revenue per patient day $53.4 $55.0 (2.9) % Cost per patient day $28.0 $28.6 (2.1) % (1) Private duty represents long-term comprehensive hourly nursing medical care. (2) See Appendix B for reconciliation of GAAP to Non-GAAP measures.

------

![](enhabit_earningsxslidesx025.jpg)

Enhabit Home Health & Hospice 25 Hospice Segment Results – YTD 2025 ($ in millions) Year-To-Date '25 vs. '242025 2024 Net service revenue $246.2 $210.0 17.2 % Cost of service 113.7 102.6 10.8 % Gross margin 53.8 % 51.1 % General and administrative expenses 72.2 65.5 10.2 % Net income attributable to noncontrolling interests 0.5 0.4 25.0 % Segment Adjusted EBITDA(1) $59.8 $41.5 44.1 % Segment Adjusted EBITDA margin(1) 24.3 % 19.8 % Operational metrics (actual amounts) Total admissions 12,586 12,025 4.7 % Same-store total admissions growth 0.5 % Patient days 1,454,421 1,304,878 11.5 % Discharged average length of stay 104 105 (1.0) % Average daily census 3,985 3,565 11.8 % Revenue per patient day $169.3 $160.9 5.2 % Cost per patient day $78.2 $78.6 (0.5) % (1) See Appendix B for reconciliation of GAAP to Non-GAAP measures.

------

![](enhabit_earningsxslidesx026.jpg)

Enhabit Home Health & Hospice 26 Payer Sources As a % of Revenue Fourth Quarter Fiscal Year Consolidated 2025 2024 2025 2024 Medicare 64.1% 66.8% 65.8% 66.8% Medicare Advantage 24.9% 22.5% 23.9% 23.0% Managed Care 9.5% 9.2% 9.1% 9.1% Medicaid 1.1% 1.3% 0.8% 0.9% Other 0.4% 0.2% 0.4% 0.2% Total 100.0% 100.0% 100.0% 100.0% Home Health Medicare 54.0% 58.5% 55.9% 58.8% Medicare Advantage 32.6% 29.0% 31.1% 28.8% Managed Care 12.1% 11.1% 11.5% 11.1% Medicaid 0.8% 1.2% 0.9% 1.1% Other 0.5% 0.2% 0.6% 0.2% Total 100.0% 100.0% 100.0% 100.0% Hospice Medicare 97.0% 95.7% 98.2% 98.3% Managed Care 1.3% 2.4% 1.1% 1.7% Medicaid 1.7% 1.9% 0.7% —% Total 100.0% 100.0% 100.0% 100.0%

------

![](enhabit_earningsxslidesx027.jpg)

Enhabit Home Health & Hospice 27 (1) MedPAC Tab E December 2025. (2) MedPAC Tab I Hospice December 2025. (3) MedPAC Tab H Home Health December 2025. (Calculated based on 30-day home health period.) (4) AARP 2024 Survey. (5) National Health Expenditures published September 2025 by CMS. (6) Includes Medicare payments for home health and hospice services. Aging Population Cost Efficiency of Home Health Care Large and Growing Addressable Markets(5) Large and Growing Addressable Markets4 ~$317B 2033 projection for broader home health expenditures(6) ~78M 2033 projection for Medicare eligible citizens 75% of those age 50 and over want to stay in their residence as they age(4) 10x lower cost than other care settings Post-Acute Service Sector Annual Medicare Spending Average Medicare Cost Per Day Skilled Nursing Facilities (SNF)(1) $30 billion $683 Hospice(2) $28 billion $191 Home Health(3) $16 billion $64 Home health = 76 Hospice = 83 Number of people age 65 or older, by age group (millions) ~5% expected growth in target population over the next three years We are here Avg. age of our patients Outlook: Attractive Industry Tailwinds Demographic Trends and Our Ability to Deliver Cost-Effective, High-Quality Care Supports Long-Term Growth

------

![](enhabit_earningsxslidesx028.jpg)

Enhabit Home Health & Hospice 28 Appendix B

------

![](enhabit_earningsxslidesx029.jpg)

Enhabit Home Health & Hospice 29 Reconciliation of Earnings Per Share to Adjusted Diluted Earnings Per Share (in millions except $ Diluted EPS amounts) Q4 Year-To-Date 2025 2024 2025 2024 Amount Diluted EPS Amount Diluted EPS Amount Diluted EPS Amount Diluted EPS Net income (loss) attributable to Enhabit, Inc. $(38.7) (0.76) $(46.0) (0.92) $(4.6) (0.09) $(156.2) (3.11) Impairment of goodwill 39.0 — 44.0 — 39.0 — 141.3 — Impairment of intangible assets 2.3 — — — 2.3 — — — Gain on sale of investment and disposal of assets(1) — — — — (14.7) — — — Unusual or nonrecurring items that are not typical of ongoing operations (2) 1.7 — 1.1 — 5.8 — 10.0 — Provision for (benefit from) income taxes(3) 2.8 — 2.9 — (0.3) — 15.6 — Adjusted Net income (loss) attributable to Enhabit, Inc. $7.1 0.14 $2.0 0.04 $27.5 0.53 $10.7 0.21 Diluted weighted average common shares outstanding 50.7 50.2 50.8 50.2 Fully diluted weighted average common shares outstanding(4) 52.2 50.5 51.6 50.4 (1) Gain on sale of investment in 2025 resulted from the sale of Medalogix investment. (2) Unusual or nonrecurring items in the three months and year ended December 31, 2025 include costs associated with restructuring activities and severance, nonroutine litigation and third-party legal and advisory fees related to shareholder, non-shareholder and other matters, and merger and acquisition activities. Unusual or nonrecurring items in the three months ended December 31, 2024 include costs associated with nonroutine litigation and severance, and for the year ended December 31, 2024 also include costs associated with shareholder activism and the strategic review process that concluded in May 2024. (3) Income tax adjustments include the effect of a valuation allowance recorded against a portion of our deferred tax assets and the effect of permanent book-tax differences attributable to stock-based compensation. (4) Reflects diluted weighted average common shares outstanding plus potential common shares used for the calculation of adjusted diluted earnings per share.

------

![](enhabit_earningsxslidesx030.jpg)

Enhabit Home Health & Hospice 30 Reconciliation of Net Income (Loss) to Adjusted EBITDA – Consolidated ($ in millions) Fourth Quarter Year-To-Date 2025 2024 2025 2024 Net income (loss) $(38.3) $(45.8) $(2.6) $(154.0) Interest expense, net 7.4 10.1 33.8 42.9 (Benefit from) provision for income taxes (2.5) (5.5) 4.0 (4.0) Depreciation and amortization 5.0 7.9 22.5 31.5 Loss (gain) on disposal of assets(1) 0.1 (0.2) (19.1) (0.7) Impairment of goodwill 44.7 53.8 44.7 161.7 Impairment of intangible assets 3.0 — 3.0 — Stock-based compensation 6.8 3.9 16.6 11.7 Net income attributable to noncontrolling interests (0.4) (0.2) (2.0) (2.2) Unusual or nonrecurring items that are not typical of ongoing operations(2) 2.2 1.1 7.6 13.2 Adjusted EBITDA $28.0 $25.1 $108.5 $100.1 (1) Gain on sale of investment in 2025 resulted from the sale of Medalogix investment. (2) Unusual or nonrecurring items in the three months and year ended December 31, 2025 include costs associated with restructuring activities and severance, nonroutine litigation and third-party legal and advisory fees related to shareholder, non- shareholder and other matters, and merger and acquisition activities. Unusual or nonrecurring items in the three months ended December 31, 2024 include costs associated with nonroutine litigation and severance, and for the year ended December 31, 2024 also include costs associated with shareholder activism and the strategic review process that concluded in May 2024.

------

![](enhabit_earningsxslidesx031.jpg)

Enhabit Home Health & Hospice 31 Q4 Year-To-Date ($ in millions) 2025 2024 2025 2024 Income (loss) before income taxes and noncontrolling interests $(40.8) $(51.3) $1.4 $(158.0) Non-segment general and administrative expenses 24.8 24.6 107.4 113.3 Interest expense, net 7.4 10.1 33.8 42.9 Depreciation and amortization 5.0 7.9 22.5 31.5 Gain (loss) on sale of investment and disposal of assets(1) 0.1 — (19.1) — Impairment of goodwill 44.7 53.8 44.7 161.7 Impairment of intangible assets 3.0 — 3.0 — Stock-based compensation expense 6.8 3.9 16.6 11.7 Net income attributable to noncontrolling interests (0.4) (0.2) (2.0) (2.2) Total Segment Adjusted EBITDA $50.6 $48.8 $208.3 $200.9 Home Health Hospice Home Health Hospice Q4 Q4 Year-To-Date Year-To-Date ($ in millions) 2025 2024 2025 2024 2025 2024 2025 2024 Net service revenue $206.8 $200.4 $63.6 $57.8 $813.8 $824.8 $246.2 $210.0 Labor 99.0 95.9 19.1 17.1 390.1 389.5 71.9 63.8 Supplies and pharmacy 2.3 2.4 5.6 5.1 9.5 9.9 21.8 19.4 Travel 5.4 5.4 1.4 1.3 20.8 21.8 5.1 4.7 Other cost of service 1.5 1.8 4.4 4.1 6.1 7.0 14.9 14.7 Total cost of service, excluding depreciation and amortization 108.2 105.5 30.5 27.6 426.5 428.2 113.7 102.6 General and administrative salaries 48.7 48.9 16.3 14.1 188.6 193.2 59.7 54.0 Other general and administrative expenses(2) 12.6 10.2 3.1 2.9 48.7 42.2 12.5 11.5 Total general and administrative expenses 61.3 59.1 19.4 17.0 237.3 235.4 72.2 65.5 Other income — — — — — — — — Equity in net income of nonconsolidated affiliates — — — — — — — — Net income attributable to noncontrolling interests 0.3 0.3 0.1 (0.1) 1.5 1.8 0.5 0.4 Segment Adjusted EBITDA $37.0 $35.5 $13.6 $13.3 $148.5 $159.4 $59.8 $41.5 Segment Adjusted EBITDA margin(3) 17.9 % 17.7 % 21.4 % 23.0 % 18.2 % 19.3 % 24.3 % 19.8 % (1) Gain on sale of investment in 2025 resulted from the sale of Medalogix investment. (2) Other general and administrative expenses are comprised of licensing fees and other individually insignificant fees for both the Home Health and Hospice segments. (3) Segment Adjusted EBITDA margin is defined as the ratio of Segment Adjusted EBITDA to segment net service revenue. Reconciliation of Income (Loss) Before Income Taxes and Noncontrolling Interests to Segment Adjusted EBITDA and Segment Adjusted EBITDA Margin

------

![](enhabit_earningsxslidesx032.jpg)

Enhabit Home Health & Hospice 32 Reconciliation of Net Cash Provided by Operating Activities to Adjusted Free Cash Flow ($ in millions) Q4 Year-To-Date 2025 2024 2025 2024 Net cash provided by operating activities $4.3 $(4.1) $70.7 $51.2 Unusual or nonrecurring items that are not typical of ongoing operations(1) 3.5 1.1 10.1 13.2 Capital expenditures for maintenance (1.0) (0.6) (4.9) (3.7) Other working capital adjustments(2) 0.4 0.3 (2.4) (3.5) Distributions paid to noncontrolling interests of consolidated affiliates (0.8) (1.5) (2.3) (3.7) Adjusted free cash flow $6.4 $(4.8) $71.2 $53.5 (1) Unusual or nonrecurring items in the three months and year ended December 31, 2025 include costs associated with restructuring activities and severance, nonroutine litigation and third-party legal and advisory fees related to shareholder, non- shareholder and other matters, and merger and acquisition activities. Unusual or nonrecurring items in the three months ended December 31, 2024 include costs associated with nonroutine litigation and severance, and for the year ended December 31, 2024 also include costs associated with shareholder activism and the strategic review process that concluded in May 2024. (2) For 2025 and going forward, adjusted free cash flow will exclude the cash impact of unusual and nonrecurring items from both cash income tax payments (refunds), net and working capital and other. The 2024 calculations have been conformed to the current methodology, which has an impact of $1.0 million and less than $0.1 million for Q4 and the year to date period, respectively.

------

![](enhabit_earningsxslidesx033.jpg)

Enhabit Home Health & Hospice 33 Reconciliation of Gross Margin to Adjusted EBITDA Margin Q4 Year-To-Date 2025 2024 2025 2024 Gross margin as a percentage of revenue 48.7 % 48.5 % 49.0 % 48.7 % General and administrative expenses (41.5) % (40.5) % (40.9) % (41.2) % Stock-based compensation 2.5 % 1.4 % 1.6 % 1.1 % Noncontrolling interests (0.1) % (0.1) % (0.2) % (0.2) % Unusual or nonrecurring items that are not typical of ongoing operations(1) 0.8 % 0.4 % 0.7 % 1.3 % Adjusted EBITDA Margin 10.4 % 9.7 % 10.2 % 9.7 % (1) Unusual or nonrecurring items in the three months and year ended December 31, 2025 include costs associated with restructuring activities and severance, nonroutine litigation and third-party legal and advisory fees related to shareholder, non-shareholder and other matters, and merger and acquisition activities. Unusual or nonrecurring items in the three months ended December 31, 2024 include costs associated with nonroutine litigation and severance, and for the year ended December 31, 2024 also include costs associated with shareholder activism and the strategic review process that concluded in May 2024.

------

![](enhabit_earningsxslidesx034.jpg)

Enhabit Home Health & Hospice 34 Reconciliation of Net Income (Loss) to Trailing Twelve-Month Adjusted EBITDA ($ in millions) Quarter Ended Trailing Twelve Months Ended March 31, June 30, September 30, December 31, December 30, December 31, 2025 2025 2025 2025 2025 2024 Net income (loss) $18.4 $5.7 $11.6 $(38.3) $(2.6) $(154.0) Interest expense and amortization of debt discounts and fees 9.4 8.7 8.3 7.4 33.8 42.9 Provision for (benefit from) income taxes 7.4 2.3 (3.2) (2.5) 4.0 (4.0) Depreciation and amortization 6.3 5.7 5.5 5.0 22.5 31.5 (Gain) loss on sale of investment and disposal of assets(1) (19.3) — 0.1 0.1 (19.1) (0.7) Impairment of goodwill — — — 47.7 47.7 161.7 Stock-based compensation 4.0 3.6 2.2 6.8 16.6 11.7 Net income attributable to noncontrolling interests (0.6) (0.5) (0.5) (0.4) (2.0) (2.2) Unusual or nonrecurring items that are not typical of ongoing operations(2)(3)(4)(5)(6) 1.0 1.4 3.0 2.2 7.6 13.2 Adjusted EBITDA $26.6 $26.9 $27.0 $28.0 $108.5 $100.1 (1) Gain on sale of investment in the three months ended March 31, 2025 resulted from the sale of Medalogix investment. (2) Unusual or nonrecurring items in the quarter ended March 31, 2025 include was costs associated with restructuring activities and severance and nonroutine litigation. (3) Unusual or nonrecurring items in the quarter ended June 30, 2025 include costs associated with restructuring activities and severance, nonroutine litigation and third-party legal and advisory fees related to shareholder and non-shareholder matters. (4) Unusual or nonrecurring items in the quarter ended September 30, 2025 include costs associated with restructuring activities and severance, nonroutine litigation and third-party legal and advisory fees related to non-shareholder matters. (5) Unusual or nonrecurring items in the quarter ended December 31, 2025 include costs associated with restructuring activities and severance, nonroutine litigation and third-party legal and advisory fees related to shareholder, non-shareholder and other matters, and merger and acquisition activities. (6) Unusual or nonrecurring items in the year ended December 31, 2024 also include costs associated with shareholder activism, the strategic review process, nonroutine litigation, restructuring activities and severance.

------

![](enhabit_earningsxslidesx035.jpg)

Enhabit Home Health & Hospice 35 Additional Disclaimers ADDITIONAL INFORMATION AND WHERE TO FIND IT This communication may be deemed to be solicitation material in respect of the transaction between the Company, Anchor Parent, LLC and Anchor Merger Sub, Inc. The Company expects to announce a special meeting of stockholders as soon as practicable to obtain stockholder approval of the proposed transaction. In connection with the transaction, the Company intends to file relevant materials with the SEC, including a proxy statement in preliminary and definitive form. INVESTORS ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH THE SEC, INCLUDING THE PROXY STATEMENT, CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE TRANSACTION AND THE PARTIES TO THE TRANSACTION. Investors may obtain a free copy of these materials (when they are available) and other documents filed by the Company with the SEC at the SEC's website at www.sec.gov, at the Company's website at www.enhabit.com or by sending a written request to the Company in care of the Corporate Secretary, at Enhabit, Inc., 6688 N. Central Expressway, Suite 1300, Dallas, Texas 75206. PARTICIPANTS IN THE SOLICITATION The directors and executive officers of the Company, and other persons, may be deemed to be participants in the solicitation of proxies in respect of the transaction. Information regarding the Company's directors and executive officers is available in the Company's definitive proxy statement filed with the SEC on May 16, 2025 in connection with the Company's 2025 annual meeting of stockholders. This document can be obtained free of charge from the sources indicated above. Additional information regarding the interests of such participants in the solicitation of proxies in respect of the proposed transaction will be included in the proxy statement and other relevant materials to be filed with the SEC when they become available.

------